SMA Newsroom

Jul 13, 2022

Community update Biogen: ASCEND Study

The ASCEND study is a global clinical trial initiated by Biogen to evaluate if patients who have previously received treatment with risdiplam, an approved SMA drug also known as Evrysdi® (risdiplam), and may not have achieved optimal clinical outcomes (e.g., improvement or delay in disease progression), may benefit from receiving a higher dose of nusinersen, also known as Spinraza® (nusinersen).

People taking part in the study must have been previously treated with the maximum daily dose of risdiplam. While nusinersen is an approved drug for the treatment of SMA, the higher dose of nusinersen is not and is considered an investigational medication.

For more information, please click here.